When, if ever, would you consider deep venous thrombosis prophylaxis for patients with advanced epithelial ovarian cancer undergoing neoadjuvant chemotherapy?

The Khorana scoring system is a great tool when this question comes up. I use it for all my ovarian cancer patients who have measurable disease in the neoadjuvant and adjuvant settings. I re-evaluate their score every 3 months to ensure they are still candidates for VTE ppx.

Mulder et al., PMID 3060...

We do not give primary ambulatory thromboprophylaxis in patients with ovarian cancer. Khorana scoring system does not work in ovarian cancer as evidenced by data from MD Anderson Cancer Center and others. We need a better scoring system for ovarian cancer.

References:

1. Fleming et al., Gynecol Oncol...